Literature DB >> 16040390

Selective depletion strategies in allogeneic stem cell transplantation.

S Mielke1, S R Solomon, A J Barrett.   

Abstract

Despite improved prophylaxis and treatment, GvHD remains a major limitation to optimal allogeneic stem cell transplantation. Ex vivo selective depletion (SD) is a strategy to prevent GvHD, in which host-reactive donor lymphocytes are selectively eliminated from a PBSC allograft while useful donor immune function is preserved. The elimination of alloreactive and thereby GvHD-mediating T cells has been shown to be feasible in both pre-clinical and more recently clinical studies. However, SD techniques and the translational research needed for clinical application are still under development. Here we summarize and discuss the following aspects of the SD approach: selection of an appropriate allogeneic stimulator; the responder population; the alloresponse; methods for removal of alloreacting T cells; product testing; clinical considerations. Our review highlights the diversity of possible approaches and the need to develop different techniques for specific clinical applications.

Entities:  

Mesh:

Year:  2005        PMID: 16040390     DOI: 10.1080/14653240510018172

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  19 in total

Review 1.  T cell therapy in allogeneic stem cell transplantation.

Authors:  J H Frederik Falkenburg; Helen E Heslop; A John Barrett
Journal:  Biol Blood Marrow Transplant       Date:  2008-01       Impact factor: 5.742

2.  Depletion of naive T cells using clinical grade magnetic CD45RA beads: a new approach for GVHD prophylaxis.

Authors:  D Teschner; E Distler; D Wehler; M Frey; D Marandiuc; K Langeveld; M Theobald; S Thomas; W Herr
Journal:  Bone Marrow Transplant       Date:  2013-08-12       Impact factor: 5.483

3.  Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation.

Authors:  Scott R Solomon; Stephan Mielke; Bipin N Savani; Aldemar Montero; Laura Wisch; Richard Childs; Nancy Hensel; John Schindler; Victor Ghetie; Susan F Leitman; Thao Mai; Charles S Carter; Roger Kurlander; Elizabeth J Read; Ellen S Vitetta; A John Barrett
Journal:  Blood       Date:  2005-04-07       Impact factor: 22.113

Review 4.  Immunotherapy for viral and fungal infections.

Authors:  H Einsele; J Löffler; M Kapp; L Rasche; S Mielke; U G Grigoleit
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

Review 5.  Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.

Authors:  Marie Bleakley; Cameron J Turtle; Stanley R Riddell
Journal:  Expert Rev Hematol       Date:  2012-08       Impact factor: 2.929

6.  Adenosine Selectively Depletes Alloreactive T Cells to Prevent GVHD While Conserving Immunity to Viruses and Leukemia.

Authors:  Greg D Whitehill; Shoba Amarnath; Pawel Muranski; Keyvan Keyvanfar; Minoo Battiwalla; Austin J Barrett; Dhanalakshmi Chinnassamy
Journal:  Mol Ther       Date:  2016-07-06       Impact factor: 11.454

7.  Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells.

Authors:  Marie Bleakley; Shelly Heimfeld; Lori A Jones; Cameron Turtle; Diane Krause; Stanley R Riddell; Warren Shlomchik
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-11       Impact factor: 5.742

8.  Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease.

Authors:  Stephan Mielke; Katayoun Rezvani; Bipin N Savani; Raquel Nunes; Agnes S M Yong; John Schindler; Roger Kurlander; Victor Ghetie; Elizabeth J Read; Scott R Solomon; Ellen S Vitetta; A John Barrett
Journal:  Blood       Date:  2007-05-03       Impact factor: 22.113

Review 9.  Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificities.

Authors:  Matthias Wölfl; Jürgen Kuball; Matthias Eyrich; Paul G Schlegel; Philip D Greenberg
Journal:  Cytometry A       Date:  2008-11       Impact factor: 4.355

10.  Quality assessment of cellular therapies: the emerging role of molecular assays.

Authors:  David F Stroncek; Ping Jin; Jiaqiang Ren; Ji Feng; Luciano Castiello; Sara Civini; Ena Wang; Francesco M Marincola; Marianna Sabatino
Journal:  Korean J Hematol       Date:  2010-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.